In this file photo Dr. Nita Patel, Director of Antibody discovery and Vaccine development, lifts a vial with a potential coronavirus, Covid-19, vaccine at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, Covid-19.
“The safety profile and immunogenicity after only a single dose are supportive for further clinical development of [vaccine] Ad26.COV2.S at a dose level of 5x1010 vp, as a potentially protective vaccine against Covid-19,“said the report. “A single dose of Ad26.COV2.S elicited strong humoral responses in the vast majority of vaccine recipients.”
The Johnson and Johnson vaccine is the fourth in the United States to enter the final phase of clinical trials. President Donald Trump has promised that 100 million doses of a vaccine will be distributed throughout the United States by the end of the year. Trump said a vaccine could be available for distribution before the presidential election on Nov 3. —